{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:54:13Z","timestamp":1760622853644},"reference-count":302,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.4155\/fmc.12.12","type":"journal-article","created":{"date-parts":[[2012,3,15]],"date-time":"2012-03-15T10:28:21Z","timestamp":1331807301000},"page":"395-424","source":"Crossref","is-referenced-by-count":7,"title":["The Impact Of CDK Inhibition In Human Malignancies Associated With Pronounced Defects In Apoptosis: Advantages Of Multi-Targeting Small Molecules"],"prefix":"10.1080","volume":"4","author":[{"given":"J\u00f3zefa","family":"W\u0119sierska-G\u0105dek","sequence":"first","affiliation":[{"name":"Cell Cycle Regulation Group, Division: Institute of Cancer Research, Dept of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8a, 1090Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias P","family":"Kramer","sequence":"additional","affiliation":[{"name":"Molecular Targets, Department of Pharmacognosy, University of Vienna, 1090Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,3,15]]},"reference":[{"key":"e_1_3_2_2_1_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"e_1_3_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.2.307.307"},{"key":"e_1_3_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001090050351"},{"key":"e_1_3_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843"},{"key":"e_1_3_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400713"},{"issue":"9","key":"e_1_3_2_2_7_1","first-page":"1610","article-title":"Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia.","volume":"8","author":"Gale RP","year":"1994","unstructured":"Gale RP , Caligaris-CappioF, DighieroG, KeatingM, MontserratE, RaiK. Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia.Leukemia8(9), 1610\u20131614 (1994).","journal-title":"Leukemia"},{"key":"e_1_3_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.10.3537"},{"key":"e_1_3_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3590537"},{"issue":"3","key":"e_1_3_2_2_10_1","first-page":"3","article-title":"Molecular biology of chronic lymphocytic leukemia: implications for therapy.","volume":"35","author":"Reed JC","year":"1998","unstructured":"Reed JC . Molecular biology of chronic lymphocytic leukemia: implications for therapy.Semin. Hematol.35(3 Suppl. 3), 3\u201313 (1998).","journal-title":"Semin. Hematol."},{"key":"e_1_3_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-078162"},{"key":"e_1_3_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2761"},{"key":"e_1_3_2_2_13_1","unstructured":"Abbas AK LichtmanAH. Cellular and Molecular Immunology (5th Edition). Elsevier Philadelphia PA USA (2005)."},{"key":"e_1_3_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.61.070192.002301"},{"key":"e_1_3_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8266103"},{"key":"e_1_3_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.1989.Supplement_12.8"},{"issue":"6","key":"e_1_3_2_2_17_1","first-page":"305","article-title":"Cyclins: wheels within wheels.","volume":"2","author":"Pines J","year":"1991","unstructured":"Pines J . Cyclins: wheels within wheels.Cell Growth Differ.2(6), 305\u2013310 (1991).","journal-title":"Cell Growth Differ."},{"key":"e_1_3_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1747-1028-6-5"},{"key":"e_1_3_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/376313a0"},{"key":"e_1_3_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1993.tb05980.x"},{"key":"e_1_3_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90535-5"},{"key":"e_1_3_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/371254a0"},{"key":"e_1_3_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nsb0896-696"},{"key":"e_1_3_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90456-9"},{"key":"e_1_3_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.8.15.1759"},{"key":"e_1_3_2_2_26_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.7.3.331"},{"issue":"6","key":"e_1_3_2_2_27_1","first-page":"1199","article-title":"A model of the G1 phase of the cell cycle incorporating cyclin E\/cdk2 complex and retinoblastoma protein.","volume":"11","author":"Obeyesekere MN","year":"1995","unstructured":"Obeyesekere MN , HerbertJR, ZimmermanSO. A model of the G1 phase of the cell cycle incorporating cyclin E\/cdk2 complex and retinoblastoma protein.Oncogene11(6), 1199\u20131205 (1995).","journal-title":"Oncogene"},{"key":"e_1_3_2_2_28_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.813200"},{"key":"e_1_3_2_2_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.2.753"},{"key":"e_1_3_2_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/323643a0"},{"key":"e_1_3_2_2_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208619"},{"key":"e_1_3_2_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.08.009"},{"key":"e_1_3_2_2_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature01764"},{"key":"e_1_3_2_2_34_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.12.1501"},{"key":"e_1_3_2_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2008.01.013"},{"key":"e_1_3_2_2_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1881"},{"key":"e_1_3_2_2_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00652.x"},{"key":"e_1_3_2_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(03)00141-8"},{"key":"e_1_3_2_2_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.012605099"},{"key":"e_1_3_2_2_40_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2000.00614.x"},{"key":"e_1_3_2_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2007.07.018"},{"key":"e_1_3_2_2_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5334.1986"},{"key":"e_1_3_2_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.07.016"},{"key":"e_1_3_2_2_44_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101194200"},{"key":"e_1_3_2_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/11926"},{"key":"e_1_3_2_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1780"},{"key":"e_1_3_2_2_47_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00058.2009"},{"key":"e_1_3_2_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90573-8"},{"key":"e_1_3_2_2_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90572-X"},{"key":"e_1_3_2_2_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2347"},{"key":"e_1_3_2_2_51_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1583207"},{"key":"e_1_3_2_2_52_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.11.7093"},{"key":"e_1_3_2_2_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5257.1861"},{"issue":"3","key":"e_1_3_2_2_54_1","first-page":"363","article-title":"Kip1 degradation via the ubiquitin\u2013proteasome pathway.","volume":"11","author":"Tam SW","year":"1997","unstructured":"Tam SW , TheodorasAM, PaganoM. Kip1 degradation via the ubiquitin\u2013proteasome pathway.Leukemia11(Suppl. 3), 363\u2013366 (1997).","journal-title":"Leukemia"},{"key":"e_1_3_2_2_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.15.4960-4967.2001"},{"key":"e_1_3_2_2_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.4.1283-1297.2005"},{"key":"e_1_3_2_2_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.7624798"},{"key":"e_1_3_2_2_58_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.11.1464"},{"key":"e_1_3_2_2_59_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.13.9.1181"},{"key":"e_1_3_2_2_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/382325a0"},{"key":"e_1_3_2_2_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/18230"},{"key":"e_1_3_2_2_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/35095083"},{"key":"e_1_3_2_2_63_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M104431200"},{"key":"e_1_3_2_2_64_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.4.492"},{"key":"e_1_3_2_2_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.23.6672"},{"key":"e_1_3_2_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdf343"},{"key":"e_1_3_2_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(02)02113-8"},{"key":"e_1_3_2_2_68_1","doi-asserted-by":"publisher","DOI":"10.1126\/stke.2003.172.re5"},{"key":"e_1_3_2_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00452-0"},{"key":"e_1_3_2_2_70_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.10.5024"},{"key":"e_1_3_2_2_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3071"},{"key":"e_1_3_2_2_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxn024"},{"key":"e_1_3_2_2_73_1","first-page":"57","article-title":"PI3Ks in lymphocyte signaling and development.","volume":"346","author":"Okkenhaug K","year":"2010","unstructured":"Okkenhaug K , FrumanDA. PI3Ks in lymphocyte signaling and development.Curr. Top. Microbiol. Immunol.346, 57\u201385 (2010).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"e_1_3_2_2_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80595-4"},{"key":"e_1_3_2_2_75_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017729108"},{"key":"e_1_3_2_2_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.23"},{"key":"e_1_3_2_2_77_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.5.2711"},{"key":"e_1_3_2_2_78_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.9.5522"},{"key":"e_1_3_2_2_79_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.22.22.7842-7852.2002"},{"key":"e_1_3_2_2_80_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2133"},{"key":"e_1_3_2_2_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri955"},{"key":"e_1_3_2_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.008"},{"key":"e_1_3_2_2_83_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100097"},{"key":"e_1_3_2_2_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1808"},{"key":"e_1_3_2_2_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(03)00303-0"},{"key":"e_1_3_2_2_86_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3420007"},{"key":"e_1_3_2_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00779-7"},{"key":"e_1_3_2_2_88_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2753"},{"key":"e_1_3_2_2_89_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0803363"},{"key":"e_1_3_2_2_90_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/12.5.631"},{"key":"e_1_3_2_2_91_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.5.2901"},{"key":"e_1_3_2_2_92_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00650-10"},{"key":"e_1_3_2_2_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200737327"},{"key":"e_1_3_2_2_94_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6065"},{"key":"e_1_3_2_2_95_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.0110.x"},{"key":"e_1_3_2_2_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00851-08"},{"key":"e_1_3_2_2_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307405"},{"key":"e_1_3_2_2_98_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.11.5262"},{"key":"e_1_3_2_2_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0993-66"},{"issue":"12","key":"e_1_3_2_2_100_1","first-page":"2732","article-title":"Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma.","volume":"53","author":"Ye BH","year":"1993","unstructured":"Ye BH , RaoPH, ChagantiRS, Dalla-FaveraR. Cloning of bcl-6, the locus involved in chromosome translocations affecting band 3q27 in B-cell lymphoma.Cancer Res.53(12), 2732\u20132735 (1993).","journal-title":"Cancer Res."},{"issue":"11","key":"e_1_3_2_2_101_1","first-page":"2331","article-title":"Transcriptional repression by the proto-oncogene BCL-6.","volume":"12","author":"Seyfert VL","year":"1996","unstructured":"Seyfert VL , AllmanD, HeY, StaudtLM. Transcriptional repression by the proto-oncogene BCL-6.Oncogene12(11), 2331\u20132342 (1996).","journal-title":"Oncogene"},{"key":"e_1_3_2_2_102_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.14.6947"},{"key":"e_1_3_2_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.patbio.2006.04.001"},{"key":"e_1_3_2_2_104_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.042702599"},{"key":"e_1_3_2_2_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1245"},{"key":"e_1_3_2_2_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03147"},{"key":"e_1_3_2_2_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3534"},{"key":"e_1_3_2_2_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-069575"},{"key":"e_1_3_2_2_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2663"},{"key":"e_1_3_2_2_110_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2003.00048.x"},{"key":"e_1_3_2_2_111_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00013.2006"},{"key":"e_1_3_2_2_112_1","doi-asserted-by":"publisher","DOI":"10.1038\/348334a0"},{"key":"e_1_3_2_2_113_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.275.5303.1129"},{"key":"e_1_3_2_2_114_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI28281"},{"key":"e_1_3_2_2_115_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089037"},{"key":"e_1_3_2_2_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209897"},{"key":"e_1_3_2_2_117_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.4.2168-2174.1993"},{"key":"e_1_3_2_2_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.68.4.2521-2528.1994"},{"key":"e_1_3_2_2_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm830"},{"key":"e_1_3_2_2_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2889"},{"key":"e_1_3_2_2_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.03.006"},{"key":"e_1_3_2_2_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2003.10.013"},{"key":"e_1_3_2_2_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0897-917"},{"issue":"11","key":"e_1_3_2_2_124_1","first-page":"1327","article-title":"Survivin apoptosis. An interloper between cell death and cell proliferation in cancer.","volume":"79","author":"Altieri DC","year":"1999","unstructured":"Altieri DC , MarchisioPC. Survivin apoptosis. An interloper between cell death and cell proliferation in cancer.Lab. Invest.79(11), 1327\u20131333 (1999).","journal-title":"Lab. Invest."},{"key":"e_1_3_2_2_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.178"},{"key":"e_1_3_2_2_126_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-4-11"},{"key":"e_1_3_2_2_127_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.4.1435.004k01_1435_1442"},{"issue":"24","key":"e_1_3_2_2_128_1","first-page":"6097","article-title":"Survivin-deltaEx3 and survivin-2B. Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.","volume":"59","author":"Mahotka C","year":"1999","unstructured":"Mahotka C , WenzelM, SpringerE, GabbertHE, GerharzCD. Survivin-deltaEx3 and survivin-2B. Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.Cancer Res.59(24), 6097\u20136102 (1999).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_129_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210263"},{"key":"e_1_3_2_2_130_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2012"},{"issue":"12","key":"e_1_3_2_2_131_1","first-page":"3131","article-title":"Identification of a p53-dependent negative response element in the bcl-2 gene.","volume":"54","author":"Miyashita T","year":"1994","unstructured":"Miyashita T , HarigaiM, HanadaM, ReedJC. Identification of a p53-dependent negative response element in the bcl-2 gene.Cancer Res.54(12), 3131\u20133135 (1994).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205353"},{"key":"e_1_3_2_2_133_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M106643200"},{"key":"e_1_3_2_2_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08417.x"},{"key":"e_1_3_2_2_135_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.10.2870.bloodjournal85102870"},{"key":"e_1_3_2_2_136_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.12.3173.3173"},{"key":"e_1_3_2_2_137_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402389"},{"issue":"8","key":"e_1_3_2_2_138_1","first-page":"1382","article-title":"Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin\u2019s lymphomas and non-neoplastic lymphoid tissue.","volume":"9","author":"Wolowiec D","year":"1995","unstructured":"Wolowiec D , BenchaibM, PernasPet al. Expression of cell cycle regulatory proteins in chronic lymphocytic leukemias. Comparison with non-Hodgkin\u2019s lymphomas and non-neoplastic lymphoid tissue. Leukemia 9(8), 1382\u20131388 (1995).","journal-title":"Leukemia"},{"key":"e_1_3_2_2_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04901.x"},{"key":"e_1_3_2_2_140_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.18.6254-6269.2001"},{"issue":"2","key":"e_1_3_2_2_141_1","first-page":"481","article-title":"Processing of cyclin E differs between normal and tumor breast cells.","volume":"60","author":"Harwell RM","year":"2000","unstructured":"Harwell RM , PorterDC, DanesC, KeyomarsiK. Processing of cyclin E differs between normal and tumor breast cells.Cancer Res.60(2), 481\u2013489 (2000).","journal-title":"Cancer Res."},{"key":"e_1_3_2_2_142_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.2.5.464"},{"key":"e_1_3_2_2_143_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-4095"},{"key":"e_1_3_2_2_144_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.12.4694"},{"key":"e_1_3_2_2_145_1","doi-asserted-by":"publisher","DOI":"10.1002\/mc.2940140302"},{"key":"e_1_3_2_2_146_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.11.3452.3452"},{"key":"e_1_3_2_2_147_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.9.3148.3148"},{"key":"e_1_3_2_2_148_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580"},{"key":"e_1_3_2_2_149_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4723278.x"},{"issue":"4","key":"e_1_3_2_2_150_1","first-page":"534","article-title":"Alterations in TP53, cyclin D2, c-Myc, p21WAF1\/CIP1 and p27KIP1 expression associated with progression in B-CLL.","volume":"48","author":"Antosz H","year":"2010","unstructured":"Antosz H , PaterskiA, Marzec-KotarskaB, SajewiczJ, DmoszynskaA. Alterations in TP53, cyclin D2, c-Myc, p21WAF1\/CIP1 and p27KIP1 expression associated with progression in B-CLL.Folia Histochem. Cytobiol.48(4), 534\u2013541 (2010).","journal-title":"Folia Histochem. Cytobiol."},{"key":"e_1_3_2_2_151_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.814"},{"key":"e_1_3_2_2_152_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.3953209.x"},{"key":"e_1_3_2_2_153_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984"},{"key":"e_1_3_2_2_154_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119869"},{"key":"e_1_3_2_2_155_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0539"},{"key":"e_1_3_2_2_156_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.789"},{"key":"e_1_3_2_2_157_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3306"},{"key":"e_1_3_2_2_158_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-373159"},{"key":"e_1_3_2_2_159_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-139725"},{"key":"e_1_3_2_2_160_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1064921"},{"key":"e_1_3_2_2_161_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1065062"},{"key":"e_1_3_2_2_162_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1065329"},{"key":"e_1_3_2_2_163_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06868.x"},{"key":"e_1_3_2_2_164_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242606799"},{"key":"e_1_3_2_2_165_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0800121105"},{"key":"e_1_3_2_2_166_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506654102"},{"key":"e_1_3_2_2_167_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0127"},{"key":"e_1_3_2_2_168_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3105"},{"key":"e_1_3_2_2_169_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-249367"},{"key":"e_1_3_2_2_170_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-254656"},{"key":"e_1_3_2_2_171_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2232"},{"key":"e_1_3_2_2_172_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3613"},{"key":"e_1_3_2_2_173_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3179"},{"key":"e_1_3_2_2_174_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2328"},{"key":"e_1_3_2_2_175_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.7.2387"},{"key":"e_1_3_2_2_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(00)79005-1"},{"key":"e_1_3_2_2_177_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2011.02.014"},{"key":"e_1_3_2_2_178_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-2223"},{"key":"e_1_3_2_2_179_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-233718"},{"key":"e_1_3_2_2_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2007.10.012"},{"key":"e_1_3_2_2_181_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161211795049714"},{"key":"e_1_3_2_2_182_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.09.110"},{"key":"e_1_3_2_2_183_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543770903524284"},{"key":"e_1_3_2_2_184_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2907"},{"key":"e_1_3_2_2_185_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945010790711978"},{"key":"e_1_3_2_2_186_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.1.23"},{"key":"e_1_3_2_2_187_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2011.628985"},{"key":"e_1_3_2_2_188_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.235"},{"key":"e_1_3_2_2_189_1","doi-asserted-by":"publisher","DOI":"10.1002\/bip.20868"},{"key":"e_1_3_2_2_190_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.113"},{"issue":"6","key":"e_1_3_2_2_191_1","first-page":"1143","article-title":"Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.","volume":"9","author":"Sedlacek H","year":"1996","unstructured":"Sedlacek H , CzechJ, NaikRet al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int. J. Oncol. 9(6), 1143\u20131168 (1996).","journal-title":"Int. J. Oncol."},{"key":"e_1_3_2_2_192_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.9.2986"},{"key":"e_1_3_2_2_193_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1994.00771.x"},{"key":"e_1_3_2_2_194_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.0518a.x"},{"key":"e_1_3_2_2_195_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm960666x"},{"key":"e_1_3_2_2_196_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x"},{"key":"e_1_3_2_2_197_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C000446200"},{"key":"e_1_3_2_2_198_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102306200"},{"key":"e_1_3_2_2_199_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2443.2003.00627.x"},{"key":"e_1_3_2_2_200_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.8.1023"},{"key":"e_1_3_2_2_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2008.121"},{"key":"e_1_3_2_2_202_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3661"},{"key":"e_1_3_2_2_203_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.12.1278"},{"key":"e_1_3_2_2_204_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-040020"},{"key":"e_1_3_2_2_205_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.10.3804.422k36_3804_3816"},{"key":"e_1_3_2_2_206_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.393"},{"key":"e_1_3_2_2_207_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02895.x"},{"key":"e_1_3_2_2_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(00)00124-4"},{"key":"e_1_3_2_2_209_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.11.4307"},{"key":"e_1_3_2_2_210_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403139"},{"key":"e_1_3_2_2_211_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0527-2"},{"key":"e_1_3_2_2_212_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2005.03.010"},{"key":"e_1_3_2_2_213_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.s.009"},{"key":"e_1_3_2_2_214_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2276"},{"key":"e_1_3_2_2_215_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-020735"},{"key":"e_1_3_2_2_216_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0305568"},{"key":"e_1_3_2_2_217_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-008-0921-5"},{"key":"e_1_3_2_2_218_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-190256"},{"key":"e_1_3_2_2_219_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.233"},{"key":"e_1_3_2_2_220_1","unstructured":"Reddy M ArbitrarioJ JonesJ SilvermanJ HowlettA TavernaP. SNS-032 has potent antitumor activity in vivo against human leukemia and multiple myeloma xenografts. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery Biology and Clinical Applications. San Francisco CA USA 23 October 2007 (Poster A258)."},{"key":"e_1_3_2_2_221_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07136"},{"key":"e_1_3_2_2_222_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-007-9090-3"},{"key":"e_1_3_2_2_223_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0873-3"},{"key":"e_1_3_2_2_224_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.1347"},{"key":"e_1_3_2_2_225_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10738"},{"key":"e_1_3_2_2_226_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00000944"},{"key":"e_1_3_2_2_227_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11290"},{"key":"e_1_3_2_2_228_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204412"},{"key":"e_1_3_2_2_229_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-0110"},{"key":"e_1_3_2_2_230_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.113.4.1"},{"key":"e_1_3_2_2_231_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.24.5142"},{"key":"e_1_3_2_2_232_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.21211"},{"key":"e_1_3_2_2_233_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22074"},{"key":"e_1_3_2_2_234_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22400"},{"key":"e_1_3_2_2_235_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0233"},{"key":"e_1_3_2_2_236_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi217"},{"key":"e_1_3_2_2_237_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207025"},{"key":"e_1_3_2_2_238_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0320"},{"key":"e_1_3_2_2_239_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23004"},{"key":"e_1_3_2_2_240_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23024"},{"key":"e_1_3_2_2_241_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2713"},{"key":"e_1_3_2_2_242_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403295"},{"key":"e_1_3_2_2_243_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22139"},{"key":"e_1_3_2_2_244_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-011-0603-3"},{"key":"e_1_3_2_2_245_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.72"},{"key":"e_1_3_2_2_246_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.12.002"},{"key":"e_1_3_2_2_247_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-29"},{"key":"e_1_3_2_2_248_1","doi-asserted-by":"publisher","DOI":"10.2165\/11319270-000000000-00000"},{"key":"e_1_3_2_2_249_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc864"},{"key":"e_1_3_2_2_250_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902842626"},{"key":"e_1_3_2_2_251_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00164-0"},{"key":"e_1_3_2_2_252_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08420.x"},{"key":"e_1_3_2_2_253_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(99)00122-8"},{"key":"e_1_3_2_2_254_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.1056.bloodjournal8731056"},{"key":"e_1_3_2_2_255_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-172254"},{"key":"e_1_3_2_2_256_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-189795"},{"key":"e_1_3_2_2_257_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1919"},{"key":"e_1_3_2_2_258_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1979"},{"key":"e_1_3_2_2_259_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1112"},{"key":"e_1_3_2_2_260_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.313"},{"key":"e_1_3_2_2_261_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2264"},{"key":"e_1_3_2_2_262_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1276"},{"key":"e_1_3_2_2_263_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1748"},{"key":"e_1_3_2_2_264_1","doi-asserted-by":"crossref","unstructured":"Siegel-Lakhai WS RodensteinDO BeijnenJH Gianella-BorradoriA SchellensJH TalbotDC. Phase I study of seliciclib (CYC202 or R-roscovitine) in combination with gemcitabine (gem)\/cisplatin (cis) in patients with advanced non-small cell lung cancer (NSCLC). Presented at: ASCO Annual Meeting Proceedings. Orlando FL USA 13\u201317 May 2005.","DOI":"10.1200\/jco.2005.23.16_suppl.2060"},{"key":"e_1_3_2_2_265_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml100051d"},{"key":"e_1_3_2_2_266_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0324"},{"key":"e_1_3_2_2_267_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.12.7.16475"},{"key":"e_1_3_2_2_268_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0167"},{"key":"e_1_3_2_2_269_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.7.2968-2977.2004"},{"key":"e_1_3_2_2_270_1","unstructured":"Johnson AJ SmithLL RaymondCAet al. The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia. AACR 100th Annual Meeting. Abstract 4777 (2009)."},{"key":"e_1_3_2_2_271_1","doi-asserted-by":"crossref","unstructured":"Flynn JM JohnsonAJ AndritsosLet al. The cyclin dependent kinase inhibitor sch 727965 demonstrates promising pre-clinical and early clinical activity in chronic lymphocytic leukemia. 51st ASH Annual Meeting and Exposition Abstract 886 (2009).","DOI":"10.1182\/blood.V114.22.886.886"},{"key":"e_1_3_2_2_272_1","doi-asserted-by":"crossref","unstructured":"Johnson AJ SmithLL WagnerAJet al. Dinaciclib (SCH727965) Is a novel cyclin dependent kinase inhibitor that promotes selective apoptosis in CLL cells and abrogates the protective effects of microenvironment cytokines. 52nd ASH Annual Meeting and Exposition Abstract 971 (2010).","DOI":"10.1182\/blood.V116.21.971.971"},{"key":"e_1_3_2_2_273_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2006.06.003"},{"key":"e_1_3_2_2_274_1","doi-asserted-by":"crossref","unstructured":"Ahmed S MolifeR ShawHet al. Phase I dose-escalation study of ZK 304709 an oral multi-target tumor growth inhibitor (MTGI) administered for 14 days of a 28-day cycle. Presented at: ASCO Annual Meeting Proceedings. Orlando FL USA. 20 June 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.2076"},{"key":"e_1_3_2_2_275_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.146415"},{"key":"e_1_3_2_2_276_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.06.006"},{"key":"e_1_3_2_2_277_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0968-y"},{"key":"e_1_3_2_2_278_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800382h"},{"key":"e_1_3_2_2_279_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0890"},{"key":"e_1_3_2_2_280_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-1071"},{"key":"e_1_3_2_2_281_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq734"},{"key":"e_1_3_2_2_282_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025683"},{"key":"e_1_3_2_2_283_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9006559"},{"key":"e_1_3_2_2_284_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0190"},{"key":"e_1_3_2_2_285_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-09-0726"},{"key":"e_1_3_2_2_286_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2009.12.009"},{"key":"e_1_3_2_2_287_1","unstructured":"Caligiuri M BockovichN OalmannCet al. Induction of tumor regression by the broad-spectrum cyclin dependent kinase inhibitor RGB-286638. AACR 97th Annual Meeting 2006 (2006)."},{"key":"e_1_3_2_2_288_1","unstructured":"Caligiuri M Gabriele Zybarth G Ivanov I Amon P Loferer H Kley N. RGB-286638 a multi-targeted protein kinase inhibitor induces apoptosis involving the inhibition of RNA polymerase II carboxyl-terminal domain phosphorylation and the loss of the anti-apoptotic BCL2 family member Mcl-1. AACR 100th Annual Meeting 2009 Abstract 3265 (2009)."},{"key":"e_1_3_2_2_289_1","doi-asserted-by":"crossref","unstructured":"Cirstea D HideshimaT PozziSet al. RGB 286638 a novel multi-targeted small molecule inhibitor induces multiple myeloma (MM) cell death through abrogation of CDK-dependent and independent survival mechanisms. 50th ASH Annual Meeting and Exposition Abstact 2759 (2008).","DOI":"10.1182\/blood.V112.11.2759.2759"},{"key":"e_1_3_2_2_290_1","doi-asserted-by":"crossref","unstructured":"Cirstea D HideshimaT SantoLet al. A novel multi-targeted small molecule inhibitor RGB 286638 triggers apoptosis and necrosis in multiple myeloma via dual cell death pathways. AACR 100th Annual Meeting 2009 Abstract 1994 (2009).","DOI":"10.1016\/S1557-9190(11)70746-6"},{"key":"e_1_3_2_2_291_1","doi-asserted-by":"crossref","unstructured":"Cirstea D HideshimaT PozziSet al. Pleiotropic activity of the novel cyclin-dependent kinase inhibitor RGB 286638 predicts therapeutic potential in multiple myeloma. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Abstract 14602 (2008).","DOI":"10.1200\/jco.2008.26.15_suppl.14602"},{"key":"e_1_3_2_2_292_1","doi-asserted-by":"crossref","unstructured":"De Jonge M MathijssenR LoosWet al. Phase I study on RGB-286638 a novel multi-targeted protein kinase inhibitor administered as a 1-hour infusion on five consecutive days every 4 weeks in patients with recurrent or refractory solid tumors. Presented at: 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Brussels Belgium 15\u201319 November 2010.","DOI":"10.1016\/S1359-6349(10)72110-8"},{"key":"e_1_3_2_2_293_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.12.073"},{"key":"e_1_3_2_2_294_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100732t"},{"key":"e_1_3_2_2_295_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0301"},{"key":"e_1_3_2_2_296_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08427.x"},{"key":"e_1_3_2_2_297_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1069492"},{"key":"e_1_3_2_2_298_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbl040"},{"key":"e_1_3_2_2_299_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbl034"},{"key":"e_1_3_2_2_300_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq033"},{"key":"e_1_3_2_3_2_1","unstructured":"ClinicalTrials.gov. NCIC Clinical Trials Group. AT7519M in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory Non-Hodgkin\u2019s Lymphoma. www.clinicaltrials.gov\/ct2\/show\/NCT00390117"},{"key":"e_1_3_2_3_3_1","unstructured":"ClinicalTrials.gov. Agennix. Safety and Tolerability of RGB-286638 in Patients With Selected Relapsed or Refractory Hematological Malignancies. www.clinicaltrials.gov\/ct2\/show\/NCT01168882"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.12.12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:51:17Z","timestamp":1716493877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.12.12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":302,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.4155\/fmc.12.12"],"URL":"https:\/\/doi.org\/10.4155\/fmc.12.12","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}